| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
mNLS-CPP-scramble TFA does not target any specific biological protein or pathway. It is a control peptide and is therefore designed to have no known functional activity in cells. Its "target" is to serve as a non-binding, inert substance in experiments. By using this peptide in parallel with the active peptide, researchers can rule out any non-specific effects that might be caused by the chemical properties (e.g., charge, hydrophobicity) of the peptide itself rather than its specific sequence. It is a blank for biological activity.
|
|---|---|
| ln Vitro |
This control peptide has no significant in vitro biological activity. In a cell culture assay where the active peptide (mNLS-CPP-WSTF) might inhibit inflammatory gene expression, the scrambled version will have no effect. It will not inhibit the interaction between a target protein (e.g., WSTF) and its binding partners. It is not cytotoxic and does not influence cell viability. It is specifically used as a control in Western blotting, immunocytochemistry, or functional assays to verify that the observed effects are sequence-specific and not due to the peptide backbone or delivery mechanism.
|
| ln Vivo |
As a scrambled peptide, mNLS-CPP-scramble TFA has no in vivo therapeutic or pharmacological activity. It is used as a key negative control in animal models of chronic inflammatory diseases such as metabolic dysfunction-associated steatohepatitis (MASH) and osteoarthritis. When administered to an animal model, it should produce no physiological effect or alteration of disease progression, serving as a baseline to compare against the significant effect of the active peptide. Its role is to ensure the validity of the model.
|
| Enzyme Assay |
General in vitro cell-based functional assay (for use as a control): For a typical assay, cells (e.g., chondrocytes or hepatocytes) are treated with either the active mNLS-CPP-WSTF or the scrambled control peptide (0.1-10 uM) for 24-48 hours. At the end of the treatment, RNA is extracted and the expression of inflammatory genes (e.g., TNF-alpha, IL-6) is measured by qRT-PCR. The scrambled control will produce no significant change in gene expression compared to the vehicle-treated control. The active peptide will show a significant decrease in these markers. This demonstrates the specificity of the active peptide.
|
| Cell Assay |
General in vitro cell viability assay for control safety: Seed HepG2 or primary chondrocytes in 96-well plates (1×10⁴ cells/well). Treat with mNLS-CPP-scramble TFA at 0.1-200 uM for 48 hours. Assess viability via a standard MTT assay. The scrambled peptide will show no cytotoxicity, with an IC50 > 200 uM, confirming it is biologically inert and safe to use as a control. For a Caco-2 permeability assay, the scrambled peptide, like the active peptide, would be expected to have high permeability due to the CPP domain.
|
| Animal Protocol |
General in vivo animal protocol for control: In a mouse model of osteoarthritis (OA) induced by destabilization of the medial meniscus (DMM), mNLS-CPP-scramble TFA is used as a negative control. Mice are treated with intra-articular injections of the scrambled peptide (0.1-1 mg/kg) once weekly for 4 weeks. At the end of the study, joint tissues are harvested, and histological scoring is performed. The scrambled peptide will not reduce the OA score compared to a vehicle control, confirming that any therapeutic effect seen with the active peptide is due to its specific sequence.
|
| ADME/Pharmacokinetics |
As a cell-penetrating peptide, mNLS-CPP-scramble TFA is likely rapidly cleared after systemic administration, with a very short plasma half-life (< 30 minutes) due to proteolysis and renal clearance. When injected locally (e.g., intra-articularly for OA models), it is expected to remain locally and be cleared by local proteases. As a control, its PK/ADME properties are not a focus of characterization. The TFA salt form is used to enhance solubility for research applications.
|
| Toxicity/Toxicokinetics |
mNLS-CPP-scramble TFA is a synthetic peptide and is considered non-toxic. It is designed to be inert, and no significant toxicities or off-target effects are expected from this control peptide. For use as a research reagent, it is not subjected to formal toxicology studies for genotoxicity or carcinogenicity. It is handled with standard laboratory practices. Routine control at 0.15% is acceptable for impurities.
|
| References | |
| Additional Infomation |
Appearance: Lyophilized powder (as TFA salt). Molecular formula: (not disclosed). Storage: -20degC. Solubility: Soluble in water, PBS, and DMSO. Other names: Scrambled control peptide for mNLS-CPP-WSTF. Safety: For research use only; avoid inhalation and skin contact.
|
| Molecular Formula |
C219H361N69O64.XC2HF3O2
|
|---|---|
| Molecular Weight |
4984.63 (free base)
|
| Sequence |
Glu-Glu-Glu-Ala-Ala-Gly-Arg-Lys-Arg-Lys-Lys-Arg-Thr-Gly-Ser-Tyr-Pro-Lys-Asn-Ala-Lys-Lys-Pro-Ala-Pro-Glu-Lys-Ala-Leu-Ile-Glu-Lys-Lys-Asp-Lys-His-Asp-Leu-Leu-Tyr-His-His-SerEEEAAGRKRKKRTGSYPKNAKKPAPEKALIEKKDKHDLLYHHS
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
